VTX-0811

VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma[1].

12352203

C-Myc; NF-κB; TNF Receptor

Apoptosis; NF-κB

Cancer-Kinase/protease

Cancer

[VTX-0811]

[1]Feldman I, et al. VTX-0811, a first-in-class PSGL-1 blocking monoclonal antibody, repolarizes tumor associated macrophages and induces inflammation in the tumor microenvironment, leading to suppression of tumor growth in pre-clinical studies[J]. Cancer Research, 2022, 82 (12_Supplement) : 5602-5602.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991432/

Inhibitory Antibodies

No Development Reported